Single-organelle cortical transport imaging
The two-photon assay follows BDNF-containing granules in cortico-cortical projections at substantially higher spatiotemporal resolution than the prior in vivo work described by the paper.
↳ Results, Fig. 1
Abstract
Impairments in axonal transport have been implicated in the pathogenesis of tauopathies, including frontotemporal dementia and Alzheimer's disease, yet the underlying mechanisms and reversibility of these deficits are largely unknown. In particular, the impacts of tau mutations, phosphorylation and aggregation on axonal transport in vivo remain controversial. By using two-photon imaging of axonal transport of BDNF granules in the mouse cortex, we reveal that deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death. Mechanistically, these impairments are caused by the enlargement of tau envelopes on microtubules, which act as functional barriers for transport. Crucially, these deficits are reversed by inhibiting MAPK p38α. Together, our work demonstrates that tau pathology causes reversible deficits in axonal transport in vivo, posing the basis for pharmacological interventions to restore the physiological flux of axonal organelles and cargoes in tauopathies.
Key Claims
Primary findingSupported
deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death.
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
mouse-level evidence supports an early model-specific deficit, but very small female cohorts limit precision and generalisability
Abstract; Results, Fig. 2
SecondarySupported
these deficits are reversed by inhibiting MAPK p38α.
paired inhibitor experiments improve selected transport measures, though rescue is partial and treatment order is fixed
Abstract; Results, Figs. 2–4
SecondaryTentative
tau envelopes function as obstacles for axonal transport
colocalisation, pause association, and correlative microscopy do not independently manipulate envelope size or establish causation
Results, Clusters of mutant tau on microtubules hinder axonal transport; Fig. 7
SecondaryTentative
the activity of SB-239063 on axonal transport is largely dependent on the reduction of P301L tau phosphorylation levels.
phosphomutants are informative, but the inhibitor comparison being explained is non-significant and nested observations are not modeled
Results, Fig. 6
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Convergent genetic and pharmacological controls
Doxycycline suppression, the rTg21221 WT-tau line, phosphomutant constructs, and two p38 inhibitors test complementary parts of the proposed pathway.
↳ Figs. 2–6; Extended Data Fig. 1g–j
Competing interpretations are discussed
The Discussion addresses contradictory transport studies, divergent taxol findings, incomplete rescue, and the possibility that the observed structures are small pathological aggregates rather than canonical envelopes.
↳ Discussion, both subsections
Limitations
Mechanistic analyses use clustered observations
Figs. 5–7 conduct inference on neurons or axons nested within three to five neuronal preparations; plotting preparation means does not account for that dependence.
↳ Figs. 5c,d, 6b,c and 7c–e,i
Mechanistic wording exceeds reported evidence
The envelope-obstacle claim is largely correlational, while phosphorylation dependence and envelope-size restoration are stated despite non-significant direct comparisons in Figs. 6 and 7.
↳ Abstract; Figs. 6b,c and 7h,i; Discussion
Small and restricted in vivo cohorts
Central imaging comparisons use three to four mice per group and predominantly or exclusively female cohorts, limiting precision and generalisability despite paired designs.
↳ Figs. 2d, 3d and 4c,d legends
Nabu Commentary
The strongest contribution is the in vivo observation that cortical BDNF-granule transport is impaired early in rTg4510 mice and improves on selected measures after p38 inhibition. Animal-level aggregation, paired imaging, genetic controls, and a second inhibitor support that direction of effect. The quality score is constrained by neuron- and axon-level inference across a small number of culture preparations, which weakens the phosphorylation and envelope mechanism. The abstract and Discussion also present the envelope mechanism and rescue more definitively than the correlational and partly non-significant evidence warrants.
Check another paper
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Sound3.2
Confidence highContribution
3.9
The study meaningfully extends prior work by measuring BDNF-granule transport at single-organelle resolution in association-cortex projections and connecting early deficits to p38 inhibition. Its advance is strongest for the in vivo transport observation, while the detailed envelope mechanism remains less secure.
Results, Figs. 1–4; Discussion, In vivo axonal transport defects are caused by FTD-linked tau mutations
deficits in axonal transport arise in vivo at early stages of tau pathology
Methodological Rigour
2.5
Animal-level aggregation, paired imaging, genetic controls, two inhibitors, and blinded analysis support the in vivo arm. Central culture-mechanism tests nevertheless use neurons or axons as inferential observations despite clustering within three to five preparations, so the serious pseudoreplication ceiling binds.
Figs. 5c,d, 6b,c and 7c–e,i; Methods, Statistical analyses
Lighter ‘X’ symbols represent the averages per preparation.
Reporting
3.4
The progression from assay validation to in vivo rescue and cellular mechanism is easy to follow. Causal envelope language and statements of restoration or phosphorylation dependence are stronger than the correlational or non-significant comparisons support.
Abstract; Results, Figs. 6–7; Discussion, P301S/P301L mutant tau envelopes affect axonal transport
these impairments are caused by the enlargement of tau envelopes
Positioning
3.8
The paper engages conflicting in vivo transport findings, prior p38 studies, tau-envelope literature, and the taxol discrepancy. It acknowledges incomplete rescue and structural uncertainty but gives less attention to female-only central imaging, small animal samples, and model-specific limits on extrapolation to AD.
Discussion, P301S/P301L mutant tau envelopes affect axonal transport; Discussion, In vivo axonal transport defects are caused by FTD-linked tau mutations
we cannot exclude that they may correspond to small pathological aggregates
Lower confidence on Positioning — domain match limited.
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
Several reporting inconsistencies affect interpretation of transport selection, treatment ordering, and the strength assigned to non-significant mechanistic comparisons. They do not establish data invalidity but warrant caution when interpreting rescue and mechanism claims.
Research ConductClean
Animal licensing and institutional ethical approval are declared, and source data and unprocessed western blots are listed. No supplied-text evidence establishes a research-conduct concern.
Flags: 2 declared / 5 total
Reference IntegrityClean
83 references in manuscript 81 of 81 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 08 Oct 2026
Sources: Retraction Watch ✓
Readiness
Where this paper’s evidence sits on the path from initial observation to real-world use.
Mechanistic
The work provides mechanistic characterization and pharmacological proof of concept in cultured neurons and transgenic mice. Five-day treatment, partial rescue, and the absence of behavioral or patient-level outcomes keep it well before operational or clinical validation.
Results, Figs. 2–6; Discussion, In vivo axonal transport defects are caused by FTD-linked tau mutations
we limited the neflamapimod treatment to 5 days
AI-generated, human-governed. Something look off? Contact us to request a review.